GAMMA Investing LLC Sells 4,450 Shares of Dynavax Technologies Corporation $DVAX

GAMMA Investing LLC lessened its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX) by 57.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,279 shares of the biopharmaceutical company’s stock after selling 4,450 shares during the period. GAMMA Investing LLC’s holdings in Dynavax Technologies were worth $33,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. DekaBank Deutsche Girozentrale bought a new position in Dynavax Technologies in the first quarter valued at about $30,000. Caitong International Asset Management Co. Ltd grew its position in Dynavax Technologies by 5,485.7% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,304 shares during the last quarter. Moloney Securities Asset Management LLC bought a new position in Dynavax Technologies in the first quarter valued at about $131,000. Envestnet Portfolio Solutions Inc. grew its position in Dynavax Technologies by 31.1% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 13,466 shares of the biopharmaceutical company’s stock valued at $175,000 after acquiring an additional 3,197 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Dynavax Technologies during the first quarter valued at about $180,000. Institutional investors own 96.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research note on Saturday, September 27th. JMP Securities reissued a “market outperform” rating and set a $32.00 price target on shares of Dynavax Technologies in a research note on Friday, August 22nd. Finally, Wall Street Zen raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, Dynavax Technologies currently has an average rating of “Hold” and an average price target of $24.33.

Insider Activity at Dynavax Technologies

In other news, Director Scott Dunseth Myers acquired 3,800 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was purchased at an average price of $10.82 per share, for a total transaction of $41,116.00. Following the completion of the acquisition, the director directly owned 35,004 shares in the company, valued at $378,743.28. The trade was a 12.18% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 2.98% of the stock is currently owned by corporate insiders.

Dynavax Technologies Stock Performance

NASDAQ DVAX opened at $10.10 on Monday. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -21.96 and a beta of 1.13. Dynavax Technologies Corporation has a 52 week low of $9.20 and a 52 week high of $14.63. The business has a 50 day moving average price of $10.28 and a 200-day moving average price of $10.63. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.12 by $0.02. The firm had revenue of $95.44 million during the quarter, compared to the consensus estimate of $87.55 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%. As a group, equities analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.